Combining Medication Adherence Support Plus Long-Acting Injectable Antipsychotic Medication: A Post-Hoc Analysis of 3 Pilot Studies.
Psychopharmacol Bull
; 52(3): 41-57, 2022 06 27.
Article
in En
| MEDLINE
| ID: mdl-35815176
ABSTRACT
Patients with severe mental illness (SMI) who do not adhere to treatment have a lower quality of life, with more hospitalizations, interpersonal relationship conflict, homelessness, substance use problems, and incarceration compared to patients who adhere to treatment. Nonadherence to psychiatric medications has been studied for over a decade in patients diagnosed with bipolar, schizoaffective, and schizophrenia disorders with long-acting injectable antipsychotics (LAI) becoming a mainstay of adherence-focused treatment. Previous studies have shown that LAI treatment can be further optimized with the inclusion of the behavioral intervention, Customized Adherence Enhancement (CAE). It was unclear if outcomes improved similarly across the studies that varied by demographics, diagnoses, and CAE + LAI protocols. We aimed to evaluate CAE + LAI adherence outcomes in SMI by pooling three studies to better understand response to treatment in the setting of varied circumstances. Our findings show that adherence improved similarly across studies despite these differences. Furthermore, it was demonstrated that CAE + LAI improved adherence to a similar degree when primary mood and psychotic disorder cohorts were compared. As the use of LAI expands, our findings show the versatility and effectiveness of including CAE to further optimize adherence and improve other outcomes.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antipsychotic Agents
Type of study:
Guideline
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Psychopharmacol Bull
Year:
2022
Document type:
Article